<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04300790</url>
  </required_header>
  <id_info>
    <org_study_id>MEDOPP240</org_study_id>
    <nct_id>NCT04300790</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients</brief_title>
  <acronym>METALLICA</acronym>
  <official_title>Study to Evaluate the Effect of Metformin in the Prevention of Hyperglycemia in HR[+]/HER2[-] PIK3CA-mutation Advanced Breast Cancer Patients Treated With Alpelisib Plus Endocrine Therapy. Study Metallica</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedSIR</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>MedSIR</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Men and post- or induced menopausal women with ER[+] and/or PgR[+], HER2[- ] advanced BC,
      with centrally-confirmed PI3KCAMut who progressed to an aromatase inhibitor (AI) regimen.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Men and post- or induced menopausal women with ER[+] and/or PgR[+], HER2[- ] advanced BC,
      with centrally-confirmed PI3KCAMut who progressed to an aromatase inhibitor (AI) regimen.Men
      and post- or induced menopausal women with ER[+] and/or PgR[+], HER2[- ] advanced BC, with
      centrally-confirmed PI3KCAMut who progressed to an aromatase inhibitor (AI)
      regimen.Measurable or evaluable disease according to RECIST v.1.1 criteria.No prior treatment
      with fulvestrant or PI3K, AKT or mTOR inhibitors.

      No more than one prior line of chemotherapy for metastatic breast cancer (MBC). Eastern
      Cooperative Oncology Group (ECOG) Performance Status 0 - 1. No ongoing antidiabetic
      treatment.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 30, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is a multicenter, open-label, two-cohort, Simon's two stage design, phase II clinical trial.
Cohort A: Normal fasting glycemia &lt; 100 mg/dL and HbA1c &lt; 5,7: 48 patients (20 stage 1 + 28 stage 2). Patients in cohort A will receive.
Cohort B: fasting glycemia 100 mg/dL (5.6 mmol/L) to 140mg/dL (7.8 mmol/L). 20 patients (7 stage 1 + 13 stage 2).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess the rate of patients with G3-4 hyperglycemia (HG) by CTCAE v4.03 over the first 2 cycles of treatment with alpelisib (BYL719)</measure>
    <time_frame>Baseline up tp 15 months</time_frame>
    <description>The primary objective is to assess the rate of patients with G3-4 (CTCAE v4.03) hyperglycemia (HG) over the first 2 cycles of treatment with alpelisib (BYL719) (300 mg/QD) plus fulvestrant and metformin, in patients with normal fasting glycemia and HbA1c (cohort A), and in patients with high-risk criteria (cohort B).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical efficacy of alpelisib plus fulvestrant and metformin will be exploratory evaluated based on CTCAE V4.03 guidelines.</measure>
    <time_frame>Baseline up to 15 months</time_frame>
    <description>To evaluate the clinical efficacy of combining alpelisib (300 mg/QD), fulvestrant and metformin in patients with HR[+] HER2 [-], PIK3CAMut advanced BC. Efficacy will be evaluated by number and proportion of patients with objective response, clinical benefit, rate of alpelisib discontinuations and rates of all G3-4 AESIs (HG, cutaneous rash and diarrhea over the first 2 cycles and during treatment) in both cohorts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type of HG</measure>
    <time_frame>Baseline up to 15 months</time_frame>
    <description>To define the type HG in patients with G3-4 HG.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate safety and tolerability by incidence of AEs as assessed by the investigator, with severity determined through the use of NCI-CTCAE v.4.03 (in accordance with alpelisib IB).</measure>
    <time_frame>Baseline up to 15 months</time_frame>
    <description>To evaluate the safety and tolerability of the combination of alpelisib (300 mg/QD) with fulvestrant and metformin in terms of diarrhea and rash</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival [PFS]</measure>
    <time_frame>Baseline up to 15 months</time_frame>
    <description>Progression free survival [PFS] (defined as the time from the date of inclusion to the date of the first documented progression or death due to any cause. If a patient has not had an event, PFS will be censored at the date of the last adequate tumor evaluation [see RECIST 1.1]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate [ORR]</measure>
    <time_frame>Baseline up to 15 months</time_frame>
    <description>Overall response rate [ORR] (defined as the proportion of patients with best overall response -including complete response [CR] or partial response [PR]- based on local investigator's assessment (RECIST 1.1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression [TTP]</measure>
    <time_frame>Baseline up to 15 months</time_frame>
    <description>Time to progression [TTP] (defined as the time from date of randomization/start of treatment to the date of event defined as the first documented progression or death due to underlying cancer. If a patient has not had an event, time to progression is censored at the date of last adequate tumor assessment).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate [CBR]</measure>
    <time_frame>Baseline up to 15 months</time_frame>
    <description>Clinical benefit rate [CBR] (defined as the proportion of patients with a best overall response of CR or PR or SD or Non-CR/Non-PD lasting more than 24 weeks based on local investigator assessment).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">68</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>CohortA: Normal fasting glycemia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alpelisib plus metformin and fulvestrant: During the first cycle, patients will receive fulvestrant and metformin at least one-week prior alpelisib administration (D8). Alpelisib (BYL719) 300 mg PO (one tablet of 200mg and two tablets of 50mg once a day) on a continuous dosing schedule starting on Cycle 1• Metformin 500 mg BID with breakfast and dinner. After 3 days, if no GI intolerance, increase to 1000 mg BID with breakfast and dinner. If not tolerated, reduce to prior tolerated dose. Titrate to 1000mg BID over a period of at least 4 additional days.
Fulvestrant: 500 mg (intramuscular injection) on days 1 and 15 of cycle 1 (28 days); then every 4 weeks as per SoC- (day 1 of subsequent 28-days cycles).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CohortB: Fasting glycemia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alpelisib plus metformin and fulvestrant: During the first cycle, patients will receive fulvestrant and metformin at least one-week prior alpelisib administration (D8). Alpelisib (BYL719) 300 mg PO (one tablet of 200mg and two tablets of 50mg once a day) on a continuous dosing schedule starting on Cycle 1• Metformin 500 mg BID with breakfast and dinner. After 3 days, if no GI intolerance, increase to 1000 mg BID with breakfast and dinner. If not tolerated, reduce to prior tolerated dose. Titrate to 1000mg BID over a period of at least 4 additional days.
Fulvestrant: 500 mg (intramuscular injection) on days 1 and 15 of cycle 1 (28 days); then every 4 weeks as per SoC- (day 1 of subsequent 28-days cycles).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alpelisib</intervention_name>
    <description>Alpelisib (BYL719): starting dose at 300 mg/QD.; 2 tablets once a day, oral administration, continuously during 28-day cycles until disease progression or unacceptable toxicity.</description>
    <arm_group_label>CohortA: Normal fasting glycemia</arm_group_label>
    <arm_group_label>CohortB: Fasting glycemia</arm_group_label>
    <other_name>BYL719</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>500 mg BID with breakfast and dinner. After 3 days, if no (GI) intolerance, increase to 1000 mg BID with breakfast and dinner. If not tolerated, reduce to prior tolerated dose. Titrate to 1000mg BID over a period of at least 4 additional days</description>
    <arm_group_label>CohortA: Normal fasting glycemia</arm_group_label>
    <arm_group_label>CohortB: Fasting glycemia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fulvestrant</intervention_name>
    <description>fulvestrant (500 mg IM injections; loading dose 500mg every two weeks for the first month; then every 4 weeks as per standard of care [SoC].
Patients should be started on metformin and fulvestrant within 7 to 14 days prior to start on alpelisib (D1C1)</description>
    <arm_group_label>CohortA: Normal fasting glycemia</arm_group_label>
    <arm_group_label>CohortB: Fasting glycemia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed Informed Consent Form (ICF)Exclusion Criteria:

          2. Male or female patients ≥ 18 years of age at the time of signing ICF.

          3. Men and pre-menopausal women should have been treated with (LHRH) analogue

          4. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.

          5. Histologically proven diagnosed of advanced BC not amenable to curative treatment.

          6. Documented recurrent ER[+] and/or PgR[+] 8.

          7. Measurable or evaluable disease as per RECIST v.1.1 criteria.Patients with no
             measurable or evaluable disease will be considered by the study medical monitor.9.

          8. Presence of PIK3CAMut

          9. Progression on an AI regimen for advanced BC

         10. (CNS) metastasis, controlled local disease without corticoids and/or anti-epileptic
             medication is required.

         11. At least one prior line of endocrine therapy for advanced disease, or progression on,
             or within 12 months from completion of a (neo) adjuvant aromatase inhibitor.

         12. No more than one prior chemotherapy-containing regimen for the treatment of metastatic
             disease is permitted.

         13. Fasting plasma glucose (FPG) and Glycosylated Hemoglobin (HbA1c):

             Cohort A: FPG ≤100 mg/dL (5.6 mmol/L) and HbA1c &lt; 5,7 Cohort B: FPG 100 mg/dL (5.6
             mmol/L) to 140 mg/dL (7.8 mmol/L) (IFG) and HbA1c &lt; 5,7 to 6.4%

         14. Adequate organ function

         15. Patients willing and able to comply with scheduled visits

         16. Resolution of all acute toxic effects of prior anti-cancer therapy

        Exclusion Criteria:

          1. Prior treatment with a PI3K, mTOR or AKT inhibitor

          2. Prior therapy with fulvestrant for advanced BC

          3. Patients with a known hypersensitivity to alpelisib or fulvestrant, or to any of the
             excipients

          4. Patients with an established diagnosis of diabetes mellitus [DM] type I or II
             requiring anti-diabetic drugs

          5. Prior treatment with metformin.

          6. More than one prior line of chemotherapy for advanced disease.

          7. Inflammatory BC at screening.

          8. Patients receiving systemic corticosteroids within 1 week prior to start treatment
             with alpelisib (BYL719).

          9. Patients with past medical history of acute or chronic pancreatitis within 1 year
             prior to screening.

         10. Patient with impaired gastrointestinal (GI) function

         11. Patient with documented pneumonitis/interstitial lung disease

         12. Patients with clinically significant uncontrolled heart disease and/or recent cardiac
             events

         13. Subject has any other concurrent severe and/or uncontrolled medical condition

         14. Subject is currently receiving any of the following medications and cannot be
             discontinued 7 days prior to the start of the treatment:

               -  Strong inhibitors or inducers of the isoenzyme CYP3A within the last 5 days prior
                  to study entry.

               -  Inhibitors of BCRP

         15. Patients with Child-Pugh score B or C liver disease.

         16. Patients with renal failure.

         17. Patients with unresolved osteonecrosis of the jaw

         18. Subject has a history of Stevens-Johnson Syndrome (SJS), erythema multiforme (EM) or
             toxic epidermal necrolysis (TEN)

         19. Subject has received radiotherapy ≤ 4 weeks or limited field radiation for palliation

               -  2 weeks prior to randomization

         20. Subject is currently receiving or has received systemic corticosteroids ≤ 2 weeks
             prior to starting study drug, or who have not fully recovered from side effects of
             such treatment

         21. Participation in a prior investigational study within 30 days prior to the start of
             study treatment

         22. Subject has not recovered from all toxicities related to prior anticancer therapies to
             NCI CTCAE version 4.03 Grade ≤1.

         23. Subject has a concurrent malignancy or malignancy within 3 years of start of study
             treatment

         24. Subject has a known history of (HIV) infection.

         25. Subject has any other concurrent severe and/or uncontrolled medical condition

         26. Subject is not able to understand and to comply with study instructions and
             requirements.

         27. Subject is breastfeeding or pregnant woman

         28. Subject is a sexually active male unwilling to use a condom during intercourse while
             taking study treatment, and up to 6 months after stopping study treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Llombart</last_name>
    <role>Principal Investigator</role>
    <affiliation>MedSIR</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Griselda Martrat</last_name>
    <phone>34 610 176 591</phone>
    <email>griselda.martrast@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carolina Herrero</last_name>
    <email>carol.herrero@medsir.org</email>
  </overall_contact_backup>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 11, 2020</study_first_submitted>
  <study_first_submitted_qc>March 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 9, 2020</study_first_posted>
  <last_update_submitted>March 5, 2020</last_update_submitted>
  <last_update_submitted_qc>March 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ER</keyword>
  <keyword>PI3KMut</keyword>
  <keyword>HER2</keyword>
  <keyword>Metastatic</keyword>
  <keyword>unresectable</keyword>
  <keyword>breast</keyword>
  <keyword>hyperglycemia</keyword>
  <keyword>men</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Fulvestrant</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

